No abstract

Daily injections of DTPA, begun 3 days after administration of Pu239 to mice, were continued for various intervals of from 1-12 days. Significant increase in survival followed 8 or 12 days of DTPA. Treatment given for 12 days removed 43.2 per cent of the skeletal plutonium and reduced the fraction of mice with bone tumors by 42.5 per cent at the time the last control animal had died. Two days of therapy had less effect on removal and tumor incidence. Bone tumor rate increased with time after plutonium injection. It was lowered significantly by treatment given for 12 days.

Chelating agents, such as ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA) were successfully encapsulated within lipid spherules (that is, liposomes). Encapsutlated [(14)C]EDTA, given intravenously to mice, was retained longer in tissues that nonencapsulated [(14)C]EDTA. Encapsulated DTPA, given to mice 3 days after pluttonium injection, removed an additional fraction of plutonium in the liver, presumably intracellular, not available to nonencapslulated DTPA. It also further increased urinary excretion of plutonium. Introduction of chelating agents into cells by liposomal encapsulation is a promising new approach to the treatment of metal poisoning

No abstract

No abstract